JP2019512465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512465A5 JP2019512465A5 JP2018544186A JP2018544186A JP2019512465A5 JP 2019512465 A5 JP2019512465 A5 JP 2019512465A5 JP 2018544186 A JP2018544186 A JP 2018544186A JP 2018544186 A JP2018544186 A JP 2018544186A JP 2019512465 A5 JP2019512465 A5 JP 2019512465A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- alkyl
- substituted
- compound according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297450P | 2016-02-19 | 2016-02-19 | |
| US62/297,450 | 2016-02-19 | ||
| PCT/US2017/018511 WO2017143291A1 (en) | 2016-02-19 | 2017-02-17 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512465A JP2019512465A (ja) | 2019-05-16 |
| JP2019512465A5 true JP2019512465A5 (enExample) | 2020-03-26 |
| JP6956098B2 JP6956098B2 (ja) | 2021-10-27 |
Family
ID=59625486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544186A Active JP6956098B2 (ja) | 2016-02-19 | 2017-02-17 | 変異体ｐ５３機能を復元させるための方法および化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10138219B2 (enExample) |
| EP (1) | EP3416638A4 (enExample) |
| JP (1) | JP6956098B2 (enExample) |
| KR (1) | KR102868217B1 (enExample) |
| CN (2) | CN119161324B (enExample) |
| AU (1) | AU2017221472B2 (enExample) |
| CA (2) | CA3215564C (enExample) |
| IL (2) | IL286839B (enExample) |
| MX (1) | MX383904B (enExample) |
| WO (1) | WO2017143291A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383904B (es) | 2016-02-19 | 2025-03-14 | Pmv Pharmaceuticals Inc | Métodos y composiciones para restablecer la función de p53 mutante. |
| US11814373B2 (en) * | 2019-09-23 | 2023-11-14 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
| EP4149459A4 (en) * | 2020-05-12 | 2024-05-22 | PMV Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION |
| CN111686127B (zh) * | 2020-06-04 | 2022-02-15 | 华南理工大学 | 锌铁纳米材料在降解突变p53蛋白中的应用 |
| CN113750246B (zh) * | 2020-06-04 | 2023-12-05 | 华南理工大学 | ZIF-8纳米材料在降解广谱突变p53蛋白中的应用 |
| US12570645B2 (en) | 2020-06-22 | 2026-03-10 | Pmv Pharmaceuticals, Inc. | Uses of p53 x-ray co-crystal structures |
| WO2021262596A1 (en) * | 2020-06-22 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
| EP4168411A4 (en) * | 2020-06-22 | 2024-07-24 | PMV Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING FUNCTION IN P53 MUTANTS |
| CN116249689A (zh) * | 2020-06-24 | 2023-06-09 | 皮姆维制药公司 | 用于再激活突变p53的化合物的伴随诊断工具 |
| WO2021262483A1 (en) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
| CA3183081A1 (en) * | 2020-06-24 | 2021-12-30 | Arnold Levine | Combination therapy for treatment of cancer |
| US11667636B2 (en) | 2020-12-24 | 2023-06-06 | Escient Pharmaceuticals, Inc. | Modulators of Mas-related G-protein receptor X2 and related products and methods |
| WO2022213975A1 (en) * | 2021-04-08 | 2022-10-13 | Jacobio Pharmaceuticals Co., Ltd. | Compounds targeting y220c mutant of p53 |
| UY39890A (es) * | 2021-08-10 | 2023-03-31 | Jacobio Pharmaceuticals Co Ltd | Compuestos con diana en mutante de p53 |
| CN117916230A (zh) * | 2021-08-27 | 2024-04-19 | 杭州紫晶医药科技有限公司 | 作为p53调节剂的化合物 |
| WO2023147419A2 (en) | 2022-01-27 | 2023-08-03 | Pmv Pharmaceuticals, Inc. | Deuterated compounds for restoring mutant p53 function |
| WO2024017384A1 (zh) * | 2022-07-22 | 2024-01-25 | 深圳众格生物科技有限公司 | 恢复p53突变功能的化合物及其应用 |
| WO2024041503A1 (en) * | 2022-08-22 | 2024-02-29 | Jacobio Pharmaceuticals Co., Ltd. | Compounds targeting y220c mutant of p53 |
| WO2024083223A1 (zh) * | 2022-10-21 | 2024-04-25 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| CN120265637A (zh) * | 2022-12-08 | 2025-07-04 | 北京加科思新药研发有限公司 | 靶向p53突变体的化合物 |
| WO2025031471A1 (zh) * | 2023-08-09 | 2025-02-13 | 德睿智药(苏州)新药研发有限公司 | 用于调节p53功能的新型杂环类化合物 |
| AU2024295989B2 (en) | 2023-10-20 | 2026-08-13 | Nutshell Therapeutics (Shanghai) Co., Ltd. | N-sulfonamide nitrogen-containing fused heterocyclic compound, and application thereof |
| WO2025242903A1 (en) * | 2024-05-24 | 2025-11-27 | Onco3R Therapeutics Bv | Compounds and pharmaceutical compositions thereof for the treatment of proliferative diseases |
| WO2026025042A1 (en) | 2024-07-26 | 2026-01-29 | Dana-Farber Cancer Institute, Inc. | P53 targeting compounds and uses thereof |
| WO2026067649A1 (zh) * | 2024-09-27 | 2026-04-02 | 奇树医药公司 | 恢复p53突变功能的化合物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000032175A2 (en) * | 1998-12-02 | 2000-06-08 | Pfizer Products Inc. | METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY |
| US6770652B2 (en) * | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
| EP1689710A1 (en) * | 2003-11-25 | 2006-08-16 | Novo Nordisk A/S | Indole derivatives for use as chemical uncoupler |
| US7601714B2 (en) | 2004-07-08 | 2009-10-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of PKC-theta |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| EP2268658B1 (en) | 2008-03-13 | 2015-12-09 | Universita'Degli Studi di Trieste | Peptides and aptamers thereof as specific modulators of mutant p53 function |
| RS54165B1 (sr) * | 2008-04-16 | 2015-12-31 | Karo Bio Ab | Novi ligandi za estrogenski receptor |
| GB0808282D0 (en) * | 2008-05-07 | 2008-06-11 | Medical Res Council | Compounds for use in stabilizing p53 mutants |
| HUE027755T2 (en) * | 2009-03-27 | 2016-11-28 | Merck Sharp & Dohme | Inhibitors of hepatitis C virus replication |
| DE102010049877A1 (de) | 2010-11-01 | 2012-05-03 | Merck Patent Gmbh | 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate |
| RU2598842C2 (ru) | 2011-01-20 | 2016-09-27 | Мерк Шарп Энд Домэ Корп. | Антагонисты рецептора минералокортикоидов |
| GB201110390D0 (en) | 2011-06-20 | 2011-08-03 | Medical Res Council | Compounds for use in stabilising p53 mutants |
| SG10201601840RA (en) * | 2011-09-09 | 2016-04-28 | Agency Science Tech & Res | P53 activating peptides |
| WO2013101911A2 (en) | 2011-12-28 | 2013-07-04 | Allergan, Inc. | Benzimidazole derivatives as selective blockers of persistent sodium current |
| US8822689B2 (en) | 2012-09-19 | 2014-09-02 | Merial Limited | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof |
| EP3145512B1 (en) * | 2014-05-19 | 2019-07-17 | Jiangsu Hengrui Medicine Co., Ltd. | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors |
| WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| CN104672241B (zh) * | 2015-01-29 | 2018-04-24 | 王磊 | 吡咯并[2,3-d]嘧啶类化合物及其用途 |
| MX383904B (es) | 2016-02-19 | 2025-03-14 | Pmv Pharmaceuticals Inc | Métodos y composiciones para restablecer la función de p53 mutante. |
-
2017
- 2017-02-17 MX MX2018009947A patent/MX383904B/es unknown
- 2017-02-17 WO PCT/US2017/018511 patent/WO2017143291A1/en not_active Ceased
- 2017-02-17 CA CA3215564A patent/CA3215564C/en active Active
- 2017-02-17 KR KR1020187026965A patent/KR102868217B1/ko active Active
- 2017-02-17 CN CN202411302298.1A patent/CN119161324B/zh active Active
- 2017-02-17 CN CN201780013450.6A patent/CN109069481A/zh active Pending
- 2017-02-17 EP EP17753995.4A patent/EP3416638A4/en not_active Withdrawn
- 2017-02-17 IL IL286839A patent/IL286839B/en unknown
- 2017-02-17 CA CA3010847A patent/CA3010847C/en active Active
- 2017-02-17 US US15/436,333 patent/US10138219B2/en active Active
- 2017-02-17 JP JP2018544186A patent/JP6956098B2/ja active Active
- 2017-02-17 AU AU2017221472A patent/AU2017221472B2/en active Active
-
2018
- 2018-08-15 IL IL261175A patent/IL261175B/en unknown
- 2018-10-18 US US16/163,829 patent/US10640485B2/en active Active
-
2020
- 2020-03-16 US US16/819,934 patent/US11339141B2/en active Active
-
2022
- 2022-02-24 US US17/679,568 patent/US20220213062A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023203112B2 (en) | Peptide oligonucleotide conjugates | |
| JP2009530424A5 (enExample) | ||
| Cortez et al. | Incorporation of phosphonate into benzonaphthyridine toll-like receptor 7 agonists for adsorption to aluminum hydroxide | |
| Luu et al. | A potent inhibitor of protein sequestration by expanded triplet (CUG) repeats that shows phenotypic improvements in a Drosophila model of myotonic dystrophy | |
| Ranjan et al. | Recognition of HIV-TAR RNA using neomycin–benzimidazole conjugates | |
| JP2020513036A5 (enExample) | ||
| US11912999B2 (en) | Aptamer conjugates with N-heterocyclic carbene metal complexes for targeted drug delivery | |
| Huang et al. | Platinum (II) complexes containing aminophosphonate esters: Synthesis, characterization, cytotoxicity and action mechanism | |
| US7872027B2 (en) | Low molecular weight Myc-max inhibitors | |
| JP2013518036A5 (enExample) | ||
| CN115916343B (zh) | 卤代呫吨在肿瘤学和病毒学中的新用途 | |
| AU2014235957A1 (en) | Fluorescent-HAP: a diagnostic stain for HBV cores in cells | |
| Booijink et al. | A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis | |
| US10894035B2 (en) | Use of indole compounds to stimulate the immune system | |
| JP2024522183A (ja) | 非標準ｇ四重鎖構造に結合する化合物ならびにそれを作製および使用する方法 | |
| US9932333B2 (en) | Benzothiazole compound and medicine containing same | |
| ES2907624T3 (es) | Inhibidores de oxadiazol de HIPK2 para el tratamiento de la fibrosis renal | |
| WO2016172191A1 (en) | Compounds, compositions and methods for inhibiting cnksr1 | |
| US12544421B2 (en) | VDAC inhibitors for treating inflammatory bowel diseases | |
| CN107540624B (zh) | 热休克蛋白抑制剂及其制备方法和应用 | |
| CA2531869A1 (en) | Compounds having a fused, bicyclic moiety for binding to the minor groove of dsdna | |
| CN114907337B (zh) | 靶向cdk4或cdk6的共价抑制剂及其应用 | |
| RU2642426C1 (ru) | 1-Этил-6-фтор-4-оксо-7-(8-этокси-2-оксо-2Н-хромен-3-ил)-1,4-дигидрохинолин-3-карбоновая кислота, обладающая противотуберкулезной активностью | |
| EP4622962A1 (en) | Small molecular weight chemical compound to antagonize eph-ephrin tetramerization and inhibit bidirectional signaling | |
| WO2018017853A1 (en) | Nontoxic compounds for the treatment and prevention of herpesvirus infections |